Entries by Business Wire

, , , , , , ,

MJH Life Sciences Launches Covid-19 Coalition

MJH Life Sciences™ Launches COVID-19 Coalition — Alliance of renowned thought leaders to assemble biweekly to keep health care professionals abreast of emerging COVID-19 science and news.       September 10, 2020 11:46 AM Eastern Daylight Time CRANBURY, N.J.–(BUSINESS WIRE)–MJH Life Sciences™, the privately owned health care media company, is pleased to officially announce […]

, , , , , , , , , , ,

FDA Approves Monjuvi for Treatment of DLBCL

The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

, , , , , , , ,

MJH Life Sciences Hosts Virology Experts for “COVID-19: Race for a Vaccine” Live Webinar

This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.

, , , , , , , ,

U.S. FDA Approves Kite’s Tecartus

The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

, , , , , , , ,

U.S. FDA Accepts New Drug Application for Voclosporin

The U.S. Food and Drug Administration accepted the filing of Aurinia Pharmaceuticals Inc.’s New Drug Application (NDA) for voclosporin as a potential treatment for lupus nephritis, a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus.